Iressa
Tocris Bioscience, part of Bio-Techne | Catalog # 3000
Orally active, selective EGFR inhibitor
Key Product Details
Description
Orally active, selective EGFR inhibitor
Alternative Names
Gefitinib,ZD 1839
Product Description
Iressa is an orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts. Also inhibits growth of brain metastases in mouse model of non-small cell lung cancer.View information regarding the usage of Iressa for non-clinical studies.
Licensing Information
Sold for research purposes only under agreement from AstraZenecaProduct Specifications
Molecular Weight
446.90
Formula
C22H24ClFN4O3
Storage
Store at RT
Purity
≥98% (HPLC)
Chemical Name
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
CAS Number
184475-35-2
PubChem ID
123631
InChI Key
XGALLCVXEZPNRQ-UHFFFAOYSA-N
SMILES
FC(C=C3)=C(Cl)C=C3NC2=NC=NC1=CC(OC)=C(OCCCN4CCOCC4)C=C12
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 44.69 | 100 | |
| Ethanol | 4.47 | 10 |
Preparing Stock Solutions
for Iressa
The following data is based on the product molecular weight 446.90
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.24 mL | 11.19 mL | 22.38 mL |
| 5 mM | 0.45 mL | 2.24 mL | 4.48 mL |
| 10 mM | 0.22 mL | 1.12 mL | 2.24 mL |
| 50 mM | 0.04 mL | 0.22 mL | 0.45 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Tan Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlo. in a nude mouse model. Oncotarget. 2017 PMID: 29228726
- Baselga ZD1839 ('Iressa'), as an anticancer agent. Drugs 2000 PMID: 11129170
- McKillop Tumor penetration of gefi. (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 2005 PMID: 15827338
- Ciardiello Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin.Cancer Res. 2000 PMID: 10815932
Product Specific Notices for Iressa
For research use only
Loading...
Loading...